TX-COGNITE
9.1.2023 15:36:39 CET | Business Wire | Press release
Cognite, a global leader in industrial software, today announced four appointments to lead the company’s scaling efforts for its next stage of growth. Cognite's new executive leaders are Moe Tanabian, Chief Product Officer (CPO); Paul Lightfoot, SVP of User Experience; Emmanuelle Camus, President of Cognite EMEA; and Liat Berger, Chief Human Resources Officer (CHRO). These leaders held roles of increasing responsibility at Red Hat, Microsoft, Amazon, PTC, and Aker Solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230109005470/en/
L-R Liat Berger, CHRO; Moe Tanabian, CPO; Emmanuelle Camus, President EMEA; Paul Lightfoot, SVP UX (Photo: Business Wire)
Cognite’s CEO Girish Rishi said, "Building a high-performance team and developing our talent is a top priority. I'm pleased to welcome these leaders with diverse, global experiences, including deep technical skill sets and tenures at Fortune 500 companies. These accomplished executives will help us further scale our commitments to customers and partners as we solve the industrial data availability-to-value problem together."
Moe Tanabian, Cognite’s new Chief Product Officer, is charged with product strategy and execution, as well as product management, design, and engineering. He has been driving innovation at scale for nearly three decades, particularly in the areas of software products, AI, ML, and IoT. Tanabian recently served as Vice President and General Manager of Azure Light Edge for Microsoft, driving more than $2 billion P&L for Microsoft's portfolio of products in IoT, OT, and embedded industrial domains. Prior to his role at Microsoft, Tanabian worked for Samsung as Vice President of Smart Products and IoT, as well as Amazon, where he led the efforts to build and deliver the Amazon Android Appstore on Kindle Fire and Amazon Phone devices. Tanabian holds a master’s degree in Systems and Computer Engineering from Carleton University, Ottawa, Ontario and an MBA from the School of Business Queen’s University, Kingston, Ontario.
Liat Berger will serve as the new CHRO. She has a demonstrated track record of HR leadership with global multi-site companies and will help drive Cognite’s scale-up strategy. She has spent the last ten years at Aker Solutions and most recently served as Senior Vice President of People and Organization, Corporate, where she focused on business strategy by helping leaders identify, prioritize and build organizational capabilities, behaviors, and structures needed to support the change agenda. She also served as the Head of P&O for the Subsea Organization at Aker Solutions, which was composed of 4,500 employees distributed in 10 different locations on four different continents. Her expertise is building and balancing global companies while incorporating local realities, and she will play a key role in energizing Cognite’s global workforce. She is a graduate in Business Administration of Universidade Federal do Parana and has a specialization in Group Dynamics and People Management.
Emmanuelle Camus will assume the role of President of Cognite EMEA. She will focus on accelerating Cognite’s growth and strengthening the company’s position as a leading industrial software provider in the EMEA region in the Energy, Power, and Clean Tech and Manufacturing markets. Prior to joining Cognite, Camus spent 25 years at PTC in various leadership roles focused on business transformation and served most recently as their Senior Vice President of Alliances EMEAI. She has extensive experience in driving exponential growth in Europe & India through B2B sales and leveraging strategic alliances & partners and a strong background in solving Industry 4.0 challenges, digital transformation, Corporate Social Responsibility and Diversity, Equality & Inclusion. She is a graduate of NEOMA Business School.
Paul Lightfoot will support Tanabian as the new Senior Vice President of User Experience as Cognite doubles down on product design to allow customers to exponentially grow the number of data-literate industrial subject matter experts within their organizations. In his role, Lightfoot will lead Cognite's product design vision and strategy to meet these evolving needs as the OT industry is now being software-defined and is evolving into the fusing of physical and digital worlds at scale. Previously, he held product design leadership roles at several high-growth technology companies, most recently building out the product design/user experience practice at Red Hat as its Global Director, User Experience Product Design Team. Paul brings his passion for nurturing and developing a customer-obsessed culture to the role, as well as product management leadership and a focus on the discovery and development of product-market-fit. Paul has a degree in Management Information Systems from Bridgewater State University.
About Cognite
Cognite is a global industrial SaaS company that was established with a clear vision: to rapidly empower industrial companies with contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-heavy industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion®, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005470/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
